UC San Diego secured up to $25,771,771 from ARPA‑H to develop a patient‑specific, 3D‑bioprinted human liver under the agency’s PRINT program. The five‑year award funds multidisciplinary work to scale vascularized, immunocompetent livers built from a patient’s own cells, and to integrate AI for vascular network design and manufacturing. Project leads said the goal is to fabricate transplant‑sized livers that eliminate donor dependence and lifelong immunosuppression. The team will leverage rapid high‑resolution bioprinting technology from the Chen lab and AI‑driven design tools to address vascularization and cell‑type complexity. ARPA‑H funding is intended to accelerate de‑risking and translational steps; investigators will pursue tissue functional benchmarks required for regulatory engagement and clinical translation. Source: UC San Diego and ARPA‑H program announcement.